Ovarian response prediction in GnRH antagonist treatment for IVF using anti-Müllerian hormone

Human Reproduction

Volumn 30, Issue 1, 2015, Pages 170-178

  Hamdine, O ^a   Eijkemans, M J C ^a   Lentjes, E W G ^a   Torrance, H L ^a   Macklon, N S ^a,b   Fauser, B C J M ^a   Broekmans, F J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

anti M llerian hormone; GnRH antagonist; IVF; ovarian response

Indexed keywords

MUELLERIAN INHIBITING FACTOR; RECOMBINANT FOLLITROPIN; GONADORELIN;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; FEMALE; FERTILIZATION IN VITRO; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; INTRAUTERINE INSEMINATION; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OOCYTE RETRIEVAL; OVARIAN RESPONSE; OVARY FUNCTION; OVULATION PREDICTION; PREDICTIVE VALUE; PREGNANCY RATE; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BLOOD; MULTIVARIATE ANALYSIS; OVULATION INDUCTION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTI-MULLERIAN HORMONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MULTIVARIATE ANALYSIS; OVULATION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84922433818     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/deu266     Document Type: Article

References (40)

1. Al-Inany H, Aboulghar M. GnRH antagonist in assisted reproduction: a Cochrane review. Hum Reprod 2002;5:874-885
2. Al-Inany HG, Youssef MA, Aboulghar M, Broekmans F, Sterrenburg M, Smit J, Bou-Setta AM. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2011; 5:CD001750
3. AnDersen AN, Witjes H, Gordon K, Mannaerts B. Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pre-treatment. Hum Reprod 2011;12:3413-3423
4. Arce JC, La Marca A, Mirner KB, AnDersen AN, Fleming R. Antimullerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients. Fertil Steril 2013;6:1644-1653
5. Basir GS, WSO, Ng EH, Ho PC. Morphometric analysis of peri-implantation endometrium in patients having excessively high oestradiol concentrations after ovarian stimulation. Hum Reprod 2001;3:435-440
6. Beckers NG, Macklon NS, Eijkemans MJ, Fauser BC. Women with regular menstrual cycles and a poor response to ovarian hyperstimulation for in vitro fertilization exhibit follicular phase characteristics suggestive of ovarian aging. Fertil Steril 2002;2:291-297
7. Bosch E, Valencia I, EscuDero E, Crespo J, Simon C, Remohi J, Pellicer A. Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome. Fertil Steril 2003;6:1444-1449
8. Bosch E, Labarta E, Crespo J, Simon C, Remohi J, Jenkins J, Pellicer A. Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles. Hum Reprod 2010;8:2092-2100
9. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 2006;6:685-718
10. Broer SL, Dolleman M, Van DJ, Broeze KA, Opmeer BC, Bossuyt PM, Eijkemans MJ, Mol BW, Broekmans FJ. Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta-Analysis. Fertil Steril 2013a;2:420-429
11. Broer SL, Van DJ, Broeze KA, Dolleman M, Opmeer BC, Bossuyt P, Eijkemans MJ, Mol BW, Broekmans FJ. AdDed value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update 2013b;1:26-36
12. Fatemi HM, Popovic-Todorovic B, Humaidan P, Kol S, Banker M, Devroey P, Garcia-Velasco JA. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and freeze-All approach in GnRH antagonist protocol. Fertil Steril 2014;4:1008-1011
13. Fedorcsak P, Dale PO, Storeng R, Ertzeid G, Bjercke S, OlDereid N, Omland AK, Abyholm T, Tanbo T. Impact of overweight and unDerweight on assisted reproduction treatment. Hum Reprod 2004; 11:2523-2528
14. Heijnen EM, Eijkemans MJ, De Klerk C, PolinDer S, Beckers NG, Klinkert ER, Broekmans FJ, Passchier J, Te VelDe ER, MacklonNSet al.Amild treatment strategy for in-vitro fertilisation: a randomised non-inferiority trial. Lancet 2007;9563:743-749
15. Hohmann FP, Macklon NS, Fauser BC. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. J Clin Endocrinol Metab 2003; 1:166-173
16. Huirne JA, Homburg R, Lambalk CB. Are GnRH antagonists comparable to agonists for use in IVF? Hum Reprod 2007;11:2805-2813
17. Humaidan P, Polyzos NP, Alsbjerg B, Erb K, Mikkelsen AL, Elbaek HO, Papanikolaou EG, AnDersen CY. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Hum Reprod 2013;9:2511-2521
18. Kolibianakis EM, Venetis CA, Bontis J, Tarlatzis BC. Significantly lower pregnancy rates in the presence of progesterone elevation in patients treated with GnRH antagonists and gonadotrophins: a systematic review and meta-Analysis. Curr Pharm Biotechnol 2012;3:464-470
19. La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update 2014;1:124-140
20. Lee JR, Kim SH, Kim SM, Jee BC, Ku SY, Suh CS, Choi YM, Kim JG, Moon SY. Anti-Mullerian hormone dynamics during controlled ovarian hyperstimulation and optimal timing of measurement for outcome prediction. Hum Reprod 2010;10:2597-2604
21. Macklon NS, Stouffer RL, Giudice LC, Fauser BC. The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr Rev 2006; 2:170-207
22. Nelson SM, YatesRW, Lyall H, Jamieson M, Traynor I, Gaudoin M, Mitchell P, Ambrose P, Fleming R. Anti-Mullerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod 2009;4:867-875
23. Nichols JE, Crane MM, Higdon HL, Miller PB, Boone WR. Extremes of body mass inDex reduce in vitro fertilization pregnancy rates. Fertil Steril 2003; 3:645-647
24. Papanikolaou EG, Pozzobon C, Kolibianakis EM, Camus M, Tournaye H, Fatemi HM, Van Steirteghem A, Devroey P. InciDence and prediction of ovarian hyperstimulation syndrome in women unDergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2006;1:112-120
25. Patrelli TS, Gizzo S, Sianesi N, Levati L, Pezzuto A, Ferrari B, Bacchi MA. Anti-Mullerian hormone serum values and ovarian reserve: can it predict a Decrease in fertility after ovarian stimulation by ART cycles? PLoS One 2012;9:e44571
26. Pinborg A, Gaarslev C, Hougaard CO, Nyboe AA, AnDersen PK, Boivin J, Schmidt L. Influence of female bodyweight on IVF outcome: a longitudinal multicentre cohort study of 487 infertile couples. Reprod Biomed Online 2011;4:490-499
27. Polyzos NP, Stoop D, Blockeel C, Adriaensen P, Platteau P, Anckaert E, Smitz J, Devroey P. Anti-Mullerian hormone for the assessment of ovarian response in GnRH-Antagonist-treated oocyte donors. Reprod Biomed Online 2012;5:532-539
28. Polyzos NP, Nelson SM, Stoop D, Nwoye M, Humaidan P, Anckaert E, Devroey P, Tournaye H. Does the time interval between antimullerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization-intracytoplasmic sperm injection cycles with a gonadotropin-releasing hormone antagonist? A retrospective single-center study. Fertil Steril 2013;2:438-444
29. Seyhan A, Ata B, PolatM, SonWY, Yarali H, Dahan MH. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Hum Reprod 2013;9:2522-2528
30. Steinkampf MP, Hammond KR, Nichols JE, SlayDen SH. Effect of obesity on recombinant follicle-stimulating hormone absorption: subcutaneous versus intramuscular administration. Fertil Steril 2003;1:99-102
31. Sterrenburg MD, Veltman-Verhulst SM, Eijkemans MJ, Hughes EG, Macklon NS, Broekmans FJ, Fauser BC. Clinical outcomes in relation to the daily dose of recombinant follicle-stimulating hormone for ovarian stimulation in in vitro fertilization in presumed normal responDers younger than 39 years: a meta-Analysis. Hum Reprod Update 2011;2:184-196
32. Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod 2011;7:1768-1774
33. Tarlatzis BC, Zepiridis L, Grimbizis G, Bontis J. Clinical management of low ovarian response to stimulation for IVF: a systematic review. Hum Reprod Update 2003;1:61-76
34. Valbuena D, Martin J, De Pablo JL, Remohi J, Pellicer A, Simon C. Increasing levels of estradiol are Deleterious to embryonic implantation because they directly affect the embryo. Fertil Steril 2001;5:962-968
35. Van Der Gaast MH, Eijkemans MJ, Van Der Net JB, De Boer EJ, BurgerCW, Van Leeuwen FE, Fauser BC, Macklon NS. Optimum number of oocytes for a successful first IVF treatment cycle. Reprod Biomed Online 2006;4:476-480
36. Van Tilborg TC, Eijkemans MJ, Laven JS, KoksCA, De Bruin JP, Scheffer GJ, Van GolDe RJ, Fleischer K, Hoek A, Nap AW et al. The OPTIMIST study: optimisation of cost effectiveness through individualised FSH stimulation dosages for IVF treatment. A randomised controlled trial. BMC Womens Health 2012;12:29
37. Verberg MF, Eijkemans MJ, Macklon NS, Heijnen EM, Fauser BC, Broekmans FJ. Predictors of low response to mild ovarian stimulation initiated on cycle day 5 for IVF. Hum Reprod 2007; 7:1919-1924
38. Verberg MF, Macklon NS, Nargund G, Frydman R, Devroey P, Broekmans FJ, Fauser BC. Mild ovarian stimulation for IVF. Hum Reprod Update 2009; 1:13-29
39. Wittemer C, Ohl J, Bailly M, Bettahar-Lebugle K, Nisand I. Does body mass inDex of infertile women have an impact on IVF procedure and outcome? J Assist Reprod Genet 2000;10:547-552
40. Yates AP, Rustamov O, Roberts SA, Lim HY, Pemberton PW, Smith A, Nardo LG. Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF. Hum Reprod 2011;9:2353-2362